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Abstract
Binding of peptides to MHC class I (MHC-I) molecules is the most selective event in the 
processing and presentation of antigens to cytotoxic T lymphocytes (CTL) and insights into the 
mechanisms that govern peptide-MHC-I binding should facilitate our understanding of CTL 
biology. Peptide-MHC-I interactions have traditionally been quantified by the strength of the 
interaction, i.e. the binding affinity, yet it has been show that the stability of the peptide-MHC-I 
complex is a better correlate of immunogenicity compared to binding affinity. Here, we have 
experimentally analyzed peptide-MHC-I complex stability of a large panel of human MHC-I 
allotypes and generated a body of data sufficient to develop neural networks based pan-specific 
predictor of peptide-MHC-I complex stability. Integrating the neural networks predictors of 
peptide-MHC-I complex stability with state-of-the-art predictors of peptide-MHC-I binding is 
shown to significantly improve the prediction of CTL epitopes. The method is publicly available at 
www.cbs.dtu.dk/services/NetMHCstabpan.
Introduction
Binding and presentation of antigenic peptides by MHC molecules is a central event in the 
initiation of an adaptive immune response. MHC-I molecules bind peptides derived from the 
intracellular protein metabolism and present them at the cell surface for scrutiny by effector 
cells of the immune system. The resulting presentation of peptides of pathogenic origin (e.g. 
from virus or tumors) can trigger the activation of immune effector cells such as CD8+ 
cytotoxic T lymphocytes (CTLs). Peptide binding to MHC-I molecules is the single most 
selective of the many events leading to antigen presentation and considerable efforts have 
been dedicated to unravel the rules of this event. For a peptide to induce an immune 
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response it must bind with sufficient affinity and stability to the restricting MHC-I element 
to allow translocation of intact peptide-MHC-I complexes to the cell surface where it should 
remain associated long enough for circulating CD8+ CTL's of appropriate specificity to 
arrive and recognize it. Although the Law of Mass Action establishes a very close and direct 
relationship between affinity and stability, the above logic would suggest that stability might 
be the better immunogenicity correlate of the two parameters. As previously noted by us (1), 
several others have suggested that the stability of a pMHC complex correlates with 
immunogenicity (both for MHC-I (2-8), and for MHC-II (9, 10)); and it has even been 
suggested that stability correlates better with immunogenicity than affinity does (both for 
MHC-I (11-14) and MHC-II (15)). Unfortunately, these claims have been supported by 
limited and to some extend biased experimental data. The former is due to the experimental 
challenges associated with measuring complex stability, which effectively has meant that 
affinity has remained the most frequently established correlate of immunogenicity. The latter 
is due to the frequent use of predicting algorithms to select peptides of interest, which 
effectively precludes the use of immunogenicity data obtained from such predictions to 
compare the impact of affinity versus stability.
Using an HLA-A*02:01-transgenic mouse model and examining anti-vaccinia immune 
responses in an unbiased and comprehensive manner, Assarsson et al. showed that as much 
as 90% of the peptides that were found to bind with high affinity to HLA-A*02:01, 
nonetheless, were not recognized after infection (16). Asking whether lack of stability could 
be part of the explanation of this high rate of false discovery, they examined a small 
selection of 12 of these peptides spanning dominant, subdominant, cryptic, and non-
immunogenic events and concluded that “a suggestive, but not statistically significant, trend 
was noted for off-rates and dominance”. In a follow-up study (1), we examined the stability 
of a larger collection of the peptide-HLA-A*02:01 interactions reported by Assarsson et al. 
and in increasing the sample size we indeed found that stability is a significantly better 
correlate of immunogenicity than affinity is. We suggested that 30% of the peptides, which 
are non-immunogenic even though they experimentally can be verified as binders to HLA-
A*02:01, lack immunogenicity because they form MHC-I complexes of low stability. Given 
this we concluded that pMHC-I complex stability is important in the generation of T cell 
responses.
Over the last decades, accurate and reliable in silico methods capable of predicting the 
binding affinity of peptide binding to MHC-I have been developed (17-22) and these have 
been highly successful in narrowing down the search for T cell epitopes. However, the high 
false discovery rate in terms of immunogenicity (i.e. that only few of the peptides, which are 
predicted and subsequently shown to bind to MHC-I, are actually recognized by T cells 
following infection) remains a problem. Recently, we have shown that accurate predictors of 
pMHC-I complex stability can be developed and that these predict immunogenic peptides to 
form pMHC-I complexes of higher stability compared to non-immunogenic peptides (1, 23). 
These studies and corresponding predictors covered a limited set of human MHC-I 
allotypes. Here, we have generated a large body of pMHC-I complex stability data using a 
large repository of human MHC-I molecules and synthetic peptides with the aim of 
developing pan-specific predictors of MHC-I complex stability. Using this data, we report 
the development of an artificial neural network (ANN) based pan-specific predictor of 
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pMHC-I complex stability and evaluate its accuracy in predicting pMHC-I complex stability. 
By integrating this novel predictor with state-of-the-art predictors of pMHC-I binding 
affinity, we find that constructing a model with 80% weight on affinity and 20% weight on 
stability, the prediction of MHC-I ligands and T-cell epitopes is significantly improved 
beyond that of any of the two models alone. Current predictors of pMHC-I binding affinity 
are trained on a significantly larger body of data compared to available pMHC-I complex 
stability data. To access whether the relative low contribution of stability predictions was 
influenced by this unbalance in data volume, we evaluate the performance of predictors 
trained on balanced pMHC-I binding affinity data, and pMHC-I complex stability data. 
Evaluating such predictors, we find that the integrative model with similar weight on affinity 
and stability achieves optimal performance, and that this significantly outperforms the two 
individual models for prediction of both MHC ligands and T cell epitopes.
Materials and Methods
Peptide-MHC-I complex stability
9023 in-house nonameric peptides were predicted for binding to 76 HLA-I molecules using 
the NetMHCpan 2.8 prediction server (17, 18). Peptides with a predicted high affinity 
binding (<500nM or 2% rank) to multiple of the available MHC-I molecules were grouped 
into 12 peptide sets of 383 peptides each. Each peptide set was screened for pMHC-I 
complex stability on multiple MHC-I allotypes according to table 1 using a scintillation 
proximity based peptide-MHC-I dissociation assay (24). The reported half-life of pMHC-I 
complexes is the geometric mean of the half-life from two independent experiments. This 
data set was combined with an in-house small-scale data set from earlier studies arriving at a 
data set of 28,939 measurements covering 80 HLA-A and B molecules.
Data sets
For the training of the stability predictor, only data from HLA molecules characterized by at 
least one stable binding and two non-stable binding measurements (using a half-life 
threshold at 37oC of 2 hours) were included. This left a data set of pMHC-I complex half-
lifes with 28,166 measurements covering 75 HLA molecules. The data was enriched with 
1000 random natural 9mer peptides for each allele. These peptides were selected to have 
predicted affinities (using NetMHCpan-2.8) weaker than 20.000 nM, and were assigned a 
stability value of 0 hours. For retraining of the NetMHCpan method, the IEDB data set 
corresponding to version 2.8 was used. This data set consists of 136,153 peptide affinity 
measurements covering 152 distinct MHC molecules.
To generate balanced data sets where an equal number of HLA allotypes were represented 
for both stability and affinity, and for each allotype an equal number of peptide data points 
and peptide binders were represented, the following procedures were applied: For stability, 
the peptides were classified into binders and non-binders using a threshold of a stability half-
life of 1 hour. For affinity, the same classification was made using an affinity threshold of 
500 nM. Next, the subset of 58 allotypes covered by at least one binder and two non-binders 
for both affinity and stability was identified. For each of these allotypes, the number of 
binders/non-binders was identified as the lowest number from the stability and affinity data 
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set, respectively, and this number of binders/non-binders was selected from each data set. To 
ensure the highest degree of peptide diversity, this selection was done prioritizing peptides 
with measured binding to few HLA alleles. Following this procedure, a balanced data set 
was constructed for both affinity and stability each containing 17,998 data points covering 
58 alleles. As for the complete data set, these data sets were enriched with 1000 random 
natural 9mer for each allotype. As before, these peptides were selected to have predicted 
affinities (using NetMHCpan-2.8) weaker than 20.000 nM.
Artificial neural network training
Artificial neural networks (ANN) were trained as a feed-forward ANN method (25) using 
either Blosum50 encoding with a normalization factor of 5 or sparse encoded with one of the 
20 inputs being 0.9 and the remaining 19 being 0.05 with 40, 50 or 60 neurons in the hidden 
layer. In each case, the pool of unique peptides was split into five sets in a typical fivefold 
cross-validation scheme with all peptide-HLA-I stability data for a given peptide placed in 
the same group (26) (in this way, no peptide can belong to more than one group), 4/5 of the 
data was used for training and the remaining 1/5 was left for testing and early stop. Prior to 
ANN training, half-life values were transformed to a value between 0 and 1. The 
transformation used was s=2-t0/th, where s is the transformed value, th is the measured 
pMHC-I complex half-life (in hours) and t0 is a threshold value that is fitted to obtain a 
suitable distribution of the data-points for training purpose. From data show in table 2, it is 
apparent that the HLA-I allotypes display highly variable ability to form stable complexes; 
by way of example, the 95% percentile (the half-life for the top 5% most stable peptide) for 
HLA-A*03:01 was 50 times greater than the corresponding value for HLA-B*08:01 (see 
table 2). This large range in half-life values makes rescaling of data prior to ANN training 
not trivial, yet essential. Given the data, it is likely that an allotype specific threshold for 
rescaling would result in the best performing network, as information about the stability 
range of each specific allotype would be encoded in the network. However, as discussed 
later, this is not an applicable solution when developing a pan-specific predictor and as an 
alternative to allotype specific rescaling, we therefore probed different global rescaling 
thresholds in the range 0.5h to 2h to optimize the predictive performance of the networks.
For comparison to pan-specific ANNs, the Pearson's correlation coefficient (PCC) was 
calculated for each allotype included in the training set from the test set predictions. The 
PCC of each allotype was then compared between networks using a binomial test counting 
the number of times a network outperformed the other network excluding ties.
Prediction of T cell epitopes and MHC ligands
The predictive performance of the different prediction methods was evaluated on a large set 
of 9mer T cell epitopes and MHC-I ligands. T-cell epitopes were extracted from both the 
IEDB (27) and SYFPEITHI (28) databases, while MHC-I ligands where obtained from the 
SYFPEITHI database only. The evaluation data sets were filtered for predicted binding 
affinity to the reported MHC restriction element, peptide length and presence in the training 
data set as described by Jørgensen et al. (23). Briefly, all T cell epitopes and ligands were 
filtered for predicted binding affinity to the restricting MHC using NetMHCpan-2.8 with a 
rank threshold for binding of <=10% rank to exclude erroneously annotated epitopes/
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ligands. The evaluation set was further restricted to exclude HLA-peptide pairs present in the 
training data set. This filtered data set consisted of 1268 ligands representing 35 allotypes 
and 1230 epitopes representing 28 allotypes respectively. As the data were unevenly 
distributed among the allotypes, a balanced data set was extracted limiting the number of 
ligands/epitope per allotype to 100 and filtering out those allotypes with less than 10 data 
points. This final evaluation set consisted of 1058 ligands and 598 epitopes, covering 31 and 
23 different allotypes, respectively. For evaluation of methods trained on balanced binding 
data sets, the epitope and ligand data set consisted, after filtering and size restriction, of 1085 
MHC ligands and 856 T cell epitopes, covering 31 and 23 different allotypes, respectively. 
The increase in size of the evaluation data is explained by the dramatic reduction in the size 
of affinity data in balanced training data set (from 136,153 to 17,998 data points.
The performance of the ANN methods was evaluated as described earlier (17, 29) using the 
area under the receiver operating characteristic curve (AUC) performance measure: the 
source protein of each ligand/epitope was fragmented into 9mers, the reported ligand/epitope 
was annotated as positive and every other 9mer as negative. In this way, one AUC value is 
calculated for each HLA-ligand/epitope pair, and the performance of a method is reported as 
the average of the AUC over all HLA-ligand/epitope pairs.
Results
Large scale analysis of peptide-HLA-I stability
We have recently reported the generation of a predictor trained on pMHC-I stability data and 
shown that such a tool can accurately predict immunogenic MHC-I ligands and that 
combining this tool with state-of-the-art predictors of pMHC-I binding (NetMHCpan) can 
improve the predictive performance of T cell epitopes and ligands (1, 23). These studies 
were conducted on a representative set of human MHC-I allotypes and the resulting 
predictive tool has limited allotype coverage. Here, we have sought to reinforce these 
findings and generate sufficient pMHC-I stability data to develop pan-specific predictors of 
pMHC-I stability. Having 76 HLA-I allotypes and >9,000 nonameric peptides at our 
disposal, we devised a strategy to allow rapid screening of pHLA-I stability. Using 
NetMHCpan-2.8 all nonameric peptides were predicted for binding to each HLA-I allotype. 
Next, peptides predicted to bind to multiple HLA-I allotypes were grouped resulting in 
twelve peptide sets that could be used to screen for stability on 4 to 12 different allotypes 
(see table 1). This allowed us to screen the same peptide set on multiple HLA-I allotypes, 
increasing the throughput of stability assay. To fit the experimental layout, each peptide 
group was limited to contain 383 peptides. Having compiled the twelve peptide sets, each 
HLA-I allotype was screened for pMHC-I stability to the representative peptide set using a 
scintillation proximity assay based pMHC-I dissociation assay (24). For 70 of the 76 
allotypes, we were able to obtain conclusive data (data for 6 allotypes denoted in italic in 
table 1 were inconclusive). Combining this data set with a small-scale in-house data set 
resulted in a data set of 28,939 individual pMHC-I half-life data points covering 80 HLA-I 
allotypes. Peptides forming stable pMHC-I complexes (t½>1h) were found for most HLA-I 
allotypes. Of these, only data from allotypes covered by at least one binding and two non-
binding peptides (defined using a half-life threshold of 2 hours) were included in the training 
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data for the pan-specific predictor, arriving at the data set of 28,166 9-mer measurements 
covering 75 HLA molecules (see table 2).
Development of Artificial Neural Networks predictors of pHLA-I complex stability
Artificial neural networks (ANN) constitute a powerful machine-learning framework for 
data mining and ANNs have successfully been applied to develop highly efficient predictors 
of peptide-MHC-I binding (17, 18). To obtain a pan-specific predictor, the NetMHCpan 
approach earlier developed for pan-specific prediction of peptide-MHC binding affinity was 
applied. Here, an MHC-I pseudo-sequence was extracted from the polymorphic MHC-I 
residues in potential contact with the bound peptide (17), and this pseudo sequence was 
encoded together with each peptide in the training. The data were partitioned and the pan-
specific stability predictor was trained as described in Materials and Methods. Prior to 
training, the half-life values were rescaled as described in materials and methods. Both 
allotype specific and global rescaling thresholds ranging from 0.5h to 2h (here denoted t0), 
were used to identify the optimal rescaling. The highest performance was obtained using 
allotype specific rescaling values (PCC=0.693) (see figure 1). However, using allotype 
specific rescaling is not an viable option since our current aim is to develop a pan-specific 
prediction method, which by its very nature should be applicable also to allotypes without 
experimental data i.e. such a method cannot be made dependent on the availability of 
specific allotype data. Moving forward, we therefore selected the global rescaling threshold 
with the highest performance (t0=1h, PCC=0.676). This performance is slightly lower than 
the performance of the network using allotype specific rescaling, yet statistically comparable 
(p=0.901, binomial test excluding ties).
Integrating stability and affinity based predictions of pMHC-I interaction
We have previously reported that combining predictors of pMHC-I affinity with predictors 
of pMHC-I stability improve the prediction of T cell epitopes and MHC-I ligands (23). 
However, this analysis was limited to a small set of allotypes. Here, we have expanded this 
observation to a much larger set of MHC molecules. For this purpose, we extracted T cell 
epitopes and MHC-I ligands from the IEDB (27) and SYFPEITHI (28) to use as benchmark 
data sets for evaluation of the combined predictors. We applied a simple weighted average 
between affinity and stability-based predictions to identify the optimal contribution of each 
to the prediction of T cell epitopes and ligands. In a 5-fold cross validation, a ratio of 
affinity-based and stability-based predictions of 0.9:0.1 and 0.8:0.2 was consistently found 
to be optimal with respect to the prediction of MHC-I ligands and MHC-I epitopes, 
respectively (see figure 2). These combinations significantly outperformed each of the 
methods in isolation (p=0.0013, binomial test excluding ties for MHC-I ligands, and 
p=0.0005, binomial test excluding ties for MHC-I epitopes) thus consolidating our earlier 
findings (23).
Analysis of the predictive performance using balanced networks
The above analysis shows that the affinity predictions currently contribute more than the 
stability predictions to the predictive power of the optimal method. However, the differences 
in the amounts of data available for the training of the affinity and stability based predictors 
are substantial with ∼140,000 affinity measurements covering > 140 MHC-I allotypes 
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compared to a “mere” ∼28,000 stability measurements covering 75 HLA alleles. To 
investigate the impact of this difference, we extracted balanced data sets from the pMHC-I 
binding affinity and stability data sets containing the same number of “positives” and 
“negatives” data point (for details see Materials and Methods). Next, predictors of pMHC-I 
binding affinity and stability were trained as described above using a rescaling factor t0=1 
hours for the stability network. Using the afore mentioned weighted average scheme and the 
large set of IEDB and SYFPEITHI T cell epitopes and MHC ligands, we find that the 
combination of the two methods also here significantly improved the prediction beyond each 
of the individual methods with an optimal ratio of 0.7:0.3 for MHC-I ligands and 0.6:0.4 for 
MHC-I epitopes (p-value < 0.05 binomial test excluding ties) (see figure 3). Thus, using 
methods trained on size balanced data sets, the relative importance of stability predictions 
compared to that of affinity predictions is increased. Also, we consistently in both 
benchmarks find that the relative importance of stability is higher for the prediction of T cell 
epitopes than for the prediction of MHC ligands.
The source of the performance gain
Having demonstrated that inclusion stability data led to an improved predictive performance, 
we next asked ourselves what was the source of this gain in performance. The two predictors 
for binding affinity and stability are highly correlated (supplementary figure S1), and one 
could ask if the gain in performance demonstrated above results from the different nature of 
data (stability versus affinity) or simply because more data were included in the method 
development. We addressed this question by identifying the list peptides for which both 
binding affinity and stability measurements existed. This set contained 7600 peptides 
covering 58 allotypes. Given this data set, we retrained three new pan-specific predictors; a 
pan-specific affinity predictor trained on affinity peptide data set excluding the peptide data 
set with both affinity and stability measurements (termed A); a pan-specific affinity 
predictor trained on affinity data from the peptides with both affinity and stability 
measurements (termed B); and a pan-stability predictor trained on stability data from the 
peptides with both affinity and stability measurements (termed C). Both B and C were 
trained as described above using the same peptide data, identical data partitioning and same 
number of added artificial random negatives. A was trained using the NetMHCpan protocol 
described in (18). Next, linear weighted combinations of A+B and A+C were constructed 
(the optimal weights were identified separately for each method), and the performance of the 
optimal combined methods was compared on the epitope benchmark data set. Doing this, we 
find that the method combining affinity and stability (A+C) significantly outperformed the 
method combining affinity with affinity (A+B) (p-values < 0.001, binomial test excluding 
ties). This result thus demonstrates that the observed increased performance is due to the 
different nature of the data, and not due to the simple fact that more data was included.
The NetMHCstabpan server
The final pan-specific MHC class I peptide stability prediction method trained on the 
complete data set of 28,166 9-mer measurements covering 75 HLA alleles was implemented 
as a web-server which is publicly available at http://www.cbs.dtu.dk/services/
NetMHCstabpan. The server allows for prediction of pMHC-I binding stability to any HLA 
molecule of known sequence. Predictions for non-9-mer peptides are made using the 
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approximation method described in (30). Submissions are accepted in two formats, as a list 
of peptides, or as protein sequences in FASTA format. If the submission is in FASTA format, 
the predictions are made for all overlapping peptides of the user selected length(s) in the 
sequence. MHC molecules can be selected from a predefined list, or the user can upload a 
full length MHC protein sequence in FASTA format. The output is given as a table where 
each row contains the peptide, the predicted stability score, converted half-life in hours and a 
percentile rank score. The predictor also allows the user to include affinity predictions 
(calculated by NetMHCpan-2.8). Selecting this adds the predicted affinity score, the 
converted binding affinity in nM, a combination of affinity and stability scores using the 
previously described ratio of 0.8:0.2 (this ratio can be altered by the user), and a percentile 
rank score of the combined prediction score estimated from the harmonic mean of the 
stability and affinity rank values, respectively to the output.
Discussion
Binding of peptides to MHC class I molecules is the single most selective step in antigen 
presentation to CD8+ T cells, and substantial experimental and computational work has been 
dedicated to characterize this event. For a peptide to be selected for antigen presentation and 
trigger translocation to the cell surface in complex with a restricting MHC-I molecule, it 
must bind with sufficient affinity and stability. Moreover once presented, it must remain in 
the complex with the MHC on the cell surface for sufficient time to allow recognition of a 
circulating CTL. Given this, it has been argued that both binding stability and affinity are 
essential correlates to peptide immunogenicity and immune dominance, and furthermore we 
have in a set of recent publications suggested that of the two, stability is the better predictor 
of CTL immunogenicity (1, 23).
Here, we have extended these previous studies, and generated a large set of almost 30,000 
peptide stability binding measurements covering more than 75 HLA class I molecules. The 
data was created using a cost-effective screening strategy, where peptides were first 
screening for predicted binding affinity using NetMHCpan v2.8, and second partitioned into 
12 groups with predicted shared binding characteristics, allowing screening against multiple 
HLA allotypes leading to efficient identification of stable binders. From this data, we have 
constructed a pan-specific predictor of HLA-I peptide binding stability. To the best of our 
knowledge, this is the first pan-specific predictor of HLA-I stability.
This pan-specific predictor was constructed following the pipeline defined earlier for the 
pan-specific predictor of HLA-I affinity, NetMHCpan (17). The predictive performance was 
evaluated using data representing T-cell epitopes or ligands, which were downloaded from 
the SYFPEITHI and IEDB databases. Comparing the predictive performance of the stability 
predictor to that of the NetMHCpan-2.8 affinity predictor, demonstrated that the affinity-
based predictor significantly outperformed the stability prediction. However, integrating the 
two predictors with a relative weight on affinity of 80%, showed a significantly improved 
prediction of CTL epitopes compared to any of the two methods alone.
At first glance the emphasis on the affinity predictor may appears at odds with the notion 
that stability is the better correlate of CTL immunogenicity. However, comparing the relative 
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importance of stability and affinity-based predictors is not a straightforward task since there 
are two main biases that lean in favor of generating an accurate affinity based method; a 
greater quantity and diversity of data available for training of the method. The difference in 
the amount of data available for the training of affinity and stability based predictors is 
substantial with ∼140,000 affinity measurements covering > 140 MHC-I allotypes 
compared to ∼28,000 stability measurements covering 70 HLA alleles. To level this 
difference, we constructed a balanced set of binding data with the same number of allotypes 
and data points (i.e. binders and non-binders) for the affinity and stability data sets, and used 
these balanced data to retrain pan-specific binding affinity and stability predictors. When 
integrating the predictions of these two methods, and evaluating the performance on the 
large set of HLA ligands and T cell epitopes, we find that the relative weight on binding 
affinity was decreased to ∼60%. While the balanced data set has leveled the difference in 
size and allele coverage, one important aspect remains very different between the two data 
sets. From the ∼18,000 data points in the balanced data set, the stability data has 5,581 
unique peptides whereas the affinity data set has 9,161 unique peptides. This difference in 
peptide diversity is a consequence of the strategy used to select the peptides for the stability 
experiments. In retrospect, we made a suboptimal strategy decision, which unfortunately 
cannot be resolved with the existing stability data set. As more, and more diverse, stability 
data will be generated in the future, we speculate that the relative importance between the 
two methods will be shifted further in favor of emphasizing binding stability.
Even though the current tool is trained on the hitherto largest set of peptide MHC-I stability 
data, the volume of the data set remains small compared to the data available for peptide 
MHC-I affinity. Furthermore, the current tool has been trained on nonamer peptide data only 
limited to the HLA-A and HLA-B isotypes. Given this and experiences from earlier works 
(18, 21, 31, 32), we strongly expect the performance of the tools will increase as more data 
covering different peptide length, HLA isotypes/allotypes (potentially also MHC allotypes 
covering other species) become available.
It should be noted that even though we here have demonstrated a high performance for 
prediction of T cell epitopes driven by binding affinity and stability, other factors including 
self versus non-self peptides similarity (33, 34), and T cell propensity (35) are essential in 
order to characterize and predict peptide immunogenicity.
In conclusion, we have here developed the first pan-specific predictor for binding stability of 
peptide HLA-I complexes, and have demonstrated how this tool can significantly enhance 
the ability to predict T cell peptide immunogenicity. A webserver implementing the method 
is available at publicly www.cbs.dtu.dk/services/NetMHCstabpan
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Predictive performance of ANN predictors of pMHC-I complex stability
The graphic shows the average PCC,and SCC values for the predictors trained with different 
t0 thresholds.
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Figure 2. Performance of epitope/ligand predictions in terms of AUC
Predictive performance for the stability (w=0) and affinity (w=1) predictors and their 
combinations for (A) MHC-I Ligands and (B) T-cell Epitopes. The grey columns show 
combinations with significantly improve (p<0.05) performance compared to both affinity 
alone (w=1), and stability alone (w=0) and in-significant difference (p>0.05) compared to 
the optimal model (the value of w with highest AUC value). Statistical differences were 
evaluated using binomial test excluding ties.
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Figure 3. Performance of epitope/ligand predictions in terms of AUC for methods trained using 
balanced data sets
Prediction performance for the stability (w=0) and affinity (w=1) methods training on 
balanced data sets and their combinations for (A) MHC-I Ligands and (B) T-cell epitopes. 
The grey columns show combinations with significantly improve (p<0.05) performance 
compared to both affinity alone (w=1), and stability alone (w=0) and in-significant 
difference (p>0.05) compared to the optimal model (the value of w with highest AUC 
value). Statistical differences were evaluated using binomial test excluding ties.
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